Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Extrapleural Pneumonectomy /Pleurectomy Decortication, IHOC Cisplatin and Gemcitabine With Amifostine and Sodium Thiosulfate Cytoprotection for Resectable Malignant Pleural Mesothelioma

This study is ongoing, but not recruiting participants.
Dana-Farber Cancer Institute
Information provided by (Responsible Party):
Raphael Bueno, MD, Dana-Farber Cancer Institute Identifier:
First received: December 10, 2007
Last updated: September 1, 2014
Last verified: September 2014

RATIONALE: After removal of visible cancer in the chest, chemotherapy drugs are used to kill or stop tumor cells from dividing, so that they stop growing or/and die. Cisplatin is currently used safely as in intra-operative treatment for malignant pleural mesothelioma. This study is aimed to determine if the addition of gemcitabine as a second intracavitary chemotherapy can be accomplished safely.

PURPOSE: This is a Phase I trial to study the efficacy of combination chemotherapy consisting of gemcitabine and cisplatin administered in the operating room and put into the chest and abdomen for one hour. We are also looking at the effects of heating the chemotherapy to a temperature of 42 degrees Celsius and the effect of cytoprotection agents: amifostine and sodium thiosulfate to counteract potential side effects of chemotherapy.

Condition Intervention Phase
Malignant Pleural Mesothelioma
Procedure: Extrapleural pneumonectomy (EPP), Pleurectomy/Decortication
Drug: cisplatin
Drug: gemcitabine
Drug: amifostine
Drug: sodium thiosulfate
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I Trial of Extrapleural Pneumonectomy/Pleurectomy Decortication, Intrathoracic/Intraperitoneal Hyperthermic (IOHC) Cisplatin and Gemcitabine With Intravenous Amifostine and Sodium Thiosulfate Cytoprotection for Patients With Resectable Malignant Pleural Mesothelioma

Resource links provided by NLM:

Further study details as provided by Dana-Farber Cancer Institute:

Primary Outcome Measures:
  • To establish the maximally tolerated dose (MTD) of intraoperative Intrathoracic/Intraperitoneal hyperthermic gemcitabine and cisplatin combination modulated by amifostine and sodium thiosulfate in patients with malignant pleural mesothelioma. [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • To determine and quantitate the safety of this combination in these patients by defining the dose limiting toxicity. [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
  • To study the pharmacokinetics of gemcitabine and cisplatin combination administered in this way. [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Estimated Enrollment: 36
Study Start Date: November 2007
Estimated Study Completion Date: May 2015
Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)
Intervention Details:
    Procedure: Extrapleural pneumonectomy (EPP), Pleurectomy/Decortication
    Resection of the lung, the lining of the lung (pleura), the covering of the heart (pericardium), and the muscle that separates the chest and abdomen (diaphragm)
    Drug: cisplatin
    Given after the tumor is removed as a bath (perfusion) for one-hour
    Other Name: Platinol
    Drug: gemcitabine
    Given after the tumor is removed as a bath (perfusion) for one-hour
    Other Name: Gemzar
    Drug: amifostine
    Given intravenously before perfusion chemotherapy and then 2 hours after the first dose
    Drug: sodium thiosulfate
    Given intravenously immediately at the end of perfusion chemotherapy
Detailed Description:
  • This is a dose escalation study of gemcitabine with a fixed dose of cisplatin
  • Patients will undergo cytoreductive surgery, which entails the removal of the inner and outer lining of the lung (pleurectomy/decortication) with or without the lung itself (extrapleural pneumonectomy), including the lining overlying the pericardium and diaphragm. Resection of the pericardium and diaphragm are occasionally necessary to remove all visable tumor. This surgery is part of standard care for malignant pleural mesothelioma.
  • After surgery, a one hour lavage with heated cisplatin and or gemcitabine will be administered to the hemithorax (and abdominal regions if the diaphragm is no longer present).
  • Patients will remain hospitalized until they have recovered from surgery (usually 7-14 days).
  • Patients will return to the hospital during the first month after their surgery to be evaluated by the medical staff.
  • Dose escalation: 1) Three patients will be treated at the first dose level of gemcitabine. Labs will be monitored on a weekly basis, including a CBC, Chem-7, and LFT's. In the absence of developing dose-limiting toxicity (DLT) among the first 3 patients treated, dosages can be escalated. DLT will be defined as any grade 3 or higher renal toxicity, thrombocytopenia or other grade 3 toxicity not related to surgery 2) If none of these 3 patients have any toxicity, we will proceed to the next level of gemcitabine. 3) If DLT occurs in 1 of 3 patients at a given dose level, then 3 additional patients are added at that dose (for a total of 6 at this level)If no DLT occurs, we will proceed to the next level of gemcitabine. If DLT occurs in another patient, this dose is considered the maximum tolerated dose (MTD). 4) At any dose, 3 cases of DLT lead to discontinuation of recruitment at that dose and enrollment of 3 additional patients at a lower dose.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically-proven diagnosis of stages I to III malignant mesothelioma of the pleura and negative mediastinal N2 lymph nodes (Malignancy is confined to the affected hemithorax)
  • Adequate organ function including the following: adequate cardiac function, pulmonary function, renal and hepatic function and bone marrow reserve
  • Adequate overall physical activity
  • Surgical candidate for cytoreductive surgery

Exclusion Criteria:

  • Extended disease outside the ipsilateral hemithorax as proven histologically, radiologically and/or intraoperatively
  • Have received chemotherapy and or radiation therapy within the last 3 years at the time of study entry
  • Serious concomitant systemic disorders
  • Second active primary malignancy (to exclude non- melanoma skin cancer)
  • Pregnancy at the time of the operation
  • Psychiatric or addictive disorder which would preclude obtaining informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00571298

United States, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Brigham and Women's Hospital
Dana-Farber Cancer Institute
Principal Investigator: David J Sugarbaker, MD Brigham and Women's Hospital
  More Information

Additional Information:
Responsible Party: Raphael Bueno, MD, Principal Investigator, Dana-Farber Cancer Institute Identifier: NCT00571298     History of Changes
Other Study ID Numbers: 07-091 
Study First Received: December 10, 2007
Last Updated: September 1, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Dana-Farber Cancer Institute:
Extrapleural pneumonectomy
Pleurectomy Decortication
sodium thiosulfate

Additional relevant MeSH terms:
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Mesothelial
Sodium thiosulfate
Antineoplastic Agents
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Protective Agents
Antitubercular Agents
Anti-Bacterial Agents
Chelating Agents
Sequestering Agents
Radiation-Protective Agents processed this record on January 17, 2017